Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $117.19 (market cap $12.44B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 4.6× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Natera Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Natera Inc. Common Stock for 0 Days on average.
| HALO | NTRA | |
|---|---|---|
Market Cap | $12.44B | $57.03B |
Volume | 1,772,623 | 1,131,157 |
Sector | Health | Health |
52-Week High | $116.82 | $425.64 |
52-Week Low | $61.63 | $179.42 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $14.36B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halozyme Therapeutics (HALO) trades at $109.62, down 1.31% today but near its recent highs. The stock shows strong fundamental momentum with revenue growth from $1.4B in 2025 to $1.7B projected for 2026 and net income margins improving to 24.85%. Recent positive developments include a patent win against Merck in Europe and an expanded collaboration with argenx, enhancing its ENHANZE technology revenue streams. Technical indicators are bullish on moving averages, though oscillators signal neutrality with RSI at 73 suggesting overbought conditions. Support is firm at $107 with resistance at $112.
HALO presents a growth opportunity driven by robust financials and strategic expansions, but risks include high valuation multiples (P/E 32.15, P/B 86.68) and insider selling by the CEO. Analyst consensus is strongly bullish with 66.7% buy ratings and a $106 price target, though the current price exceeds this, indicating potential near-term consolidation. Investors should weigh solid earnings beats against elevated expectations and market volatility.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
